BioCryst Pharmaceuticals Management

Management criteria checks 3/4

BioCryst Pharmaceuticals' CEO is Jon Stonehouse, appointed in Jan 2007, has a tenure of 17.92 years. total yearly compensation is $4.78M, comprised of 13.9% salary and 86.1% bonuses, including company stock and options. directly owns 0.43% of the company’s shares, worth MX$135.66M. The average tenure of the management team and the board of directors is 4.8 years and 5.4 years respectively.

Key information

Jon Stonehouse

Chief executive officer

US$4.8m

Total compensation

CEO salary percentage	13.9%
CEO tenure	17.9yrs
CEO ownership	0.4%
Management average tenure	4.8yrs
Board average tenure	5.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jon Stonehouse's remuneration changed compared to BioCryst Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$124m
Jun 30 2024	n/a	n/a	-US$146m
Mar 31 2024	n/a	n/a	-US$209m
Dec 31 2023	US$5m	US$666k	-US$227m
Sep 30 2023	n/a	n/a	-US$236m
Jun 30 2023	n/a	n/a	-US$243m
Mar 31 2023	n/a	n/a	-US$226m
Dec 31 2022	US$7m	US$640k	-US$247m
Sep 30 2022	n/a	n/a	-US$193m
Jun 30 2022	n/a	n/a	-US$210m
Mar 31 2022	n/a	n/a	-US$194m
Dec 31 2021	US$7m	US$583k	-US$184m
Sep 30 2021	n/a	n/a	-US$227m
Jun 30 2021	n/a	n/a	-US$214m
Mar 31 2021	n/a	n/a	-US$209m
Dec 31 2020	US$6m	US$567k	-US$183m
Sep 30 2020	n/a	n/a	-US$125m
Jun 30 2020	n/a	n/a	-US$116m
Mar 31 2020	n/a	n/a	-US$115m
Dec 31 2019	US$2m	US$550k	-US$109m
Sep 30 2019	n/a	n/a	-US$134m
Jun 30 2019	n/a	n/a	-US$126m
Mar 31 2019	n/a	n/a	-US$107m
Dec 31 2018	US$4m	US$550k	-US$101m
Sep 30 2018	n/a	n/a	-US$93m
Jun 30 2018	n/a	n/a	-US$79m
Mar 31 2018	n/a	n/a	-US$77m
Dec 31 2017	US$4m	US$533k	-US$66m

Compensation vs Market: Jon's total compensation ($USD4.78M) is above average for companies of similar size in the MX market ($USD651.91K).

Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.

CEO

Jon Stonehouse (63 yo)

17.9yrs

Tenure

US$4,777,778

Compensation

Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co. Ltd. since joining in January 8, 2007 and also has been its President s...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jon Stonehouse	CEO, President & Executive Director	17.9yrs	US$4.78m	0.43% MX$ 135.7m
Anthony Doyle	Senior VP	4.7yrs	US$1.79m	0.082% MX$ 26.1m
Alane Barnes	Senior VP	18.3yrs	US$1.93m	0.089% MX$ 28.2m
Helen Thackray	Chief Research & Development Officer	3.8yrs	US$2.39m	0.055% MX$ 17.4m
Charles Gayer	Senior VP & Chief Commercial Officer	4.9yrs	US$1.74m	0.10% MX$ 32.0m
John Bluth	Chief Communications Officer	no data	no data	no data
Stephanie Angelini	Chief People Officer	no data	no data	no data
William Sheridan	Chief Development Officer	16.4yrs	US$2.66m	no data
Yarlagadda Babu	Chief Discovery Officer	11.2yrs	US$2.57m	no data
Jinky Rosselli	Chief Data & Insights Officer	3.1yrs	no data	no data
Philip George	Chief Strategy Officer	2.3yrs	no data	no data
Clayton Fletcher	Chief Business Development Officer	1.9yrs	no data	no data

4.8yrs

Average Tenure

57yo

Average Age

Experienced Management: BCRX *'s management team is considered experienced (4.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jon Stonehouse	CEO, President & Executive Director	17.9yrs	US$4.78m	0.43% MX$ 135.7m
Vincent Milano	Independent Director	3.4yrs	US$434.82k	0.033% MX$ 10.6m
Stephen Aselage	Independent Director	5.9yrs	US$446.90k	0.024% MX$ 7.5m
Alan Levin	Independent Director	4.8yrs	US$434.54k	0.014% MX$ 4.3m
George Abercrombie	Independent Director	13.2yrs	US$432.74k	0.0062% MX$ 2.0m
Theresa Heggie	Independent Director	6yrs	US$433.57k	0.022% MX$ 7.1m
Nancy Hutson	Independent Chair	12.9yrs	US$470.30k	0.034% MX$ 10.8m
Steven K. Galson	Independent Director	3.3yrs	US$424.40k	0.017% MX$ 5.3m
A. Sanders	Independent Director	2.8yrs	US$423.15k	0.010% MX$ 3.2m
Amy McKee	Independent Director	3.3yrs	US$422.32k	0.010% MX$ 3.2m

5.4yrs

Average Tenure

63.5yo

Average Age

Experienced Board: BCRX *'s board of directors are considered experienced (5.4 years average tenure).

BioCryst Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023

Biocryst Pharmaceuticals, Inc. Announces Executive Changes

High number of new directors

Recent updates

BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland

Insufficient new directors

BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026

BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat)

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat)

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024

BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Full year 2023 earnings released: US$1.18 loss per share (vs US$1.33 loss in FY 2022)

Forecast to breakeven in 2026

BioCryst Launches Orladeyo (Berotralstat) in Italy

BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Forecast to breakeven in 2026

BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)

Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023

Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina

BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO

BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat)

BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023

BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013

BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$0.32 loss in 2Q 2022)

BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Biocryst Pharmaceuticals, Inc. Announces Executive Changes

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile

BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

High number of new directors

BioCryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) by the Israeli Ministry of Health

High number of new directors

Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

BioCryst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

High number of new directors

BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer

FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement Activity with Bcx9930 in C3g Patients

Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) in Saudi Arabia

BioCryst Pharmaceuticals, Inc. Resumes Enrollment in BCX9930 Clinical Program

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2021)

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

High number of new directors

BioCryst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)

BioCryst Announces ORLADEYO(R) (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022

Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250

Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250

Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo(R) (Berotralstat) by Swissmedic

Biocryst Announces Health Canada Has Authorized Orladeyo® (Berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks

High number of new directors

First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.36 loss in 1Q 2021)

BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022

European Medicines Agency Grants PRIME Designation to BioCryst Pharmaceuticals, Inc.'s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva

High number of new directors

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022